Kenvue
KVUE
995 hedge funds and large institutions have $34.1B invested in Kenvue in 2024 Q2 according to their latest regulatory filings, with 140 funds opening new positions, 436 increasing their positions, 328 reducing their positions, and 93 closing their positions.
82% more call options, than puts
Call options by funds: $283M | Put options by funds: $156M
51% more first-time investments, than exits
New positions opened: 140 | Existing positions closed: 93
33% more repeat investments, than reductions
Existing positions increased: 436 | Existing positions reduced: 328
3% more funds holding
Funds holding: 963 → 995 (+32)
0.09% less ownership
Funds ownership: 98.08% → 97.99% (-0.09%)
15% less capital invested
Capital invested by funds: $40.3B → $34.1B (-$6.14B)
17% less funds holding in top 10
Funds holding in top 10: 18 → 15 (-3)
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$877M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$824M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$363M |
| 4 |
BlackRock
New York
|
+$363M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$286M |
Top Sellers
KVUE Hedge Fund Activity: Q2 2024 in Review
995 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Kenvue (KVUE) for Q2 2024, worth a combined $34.1B — down 15% from $40.3B a quarter earlier.
Buyers outnumbered sellers: 140 funds opened new KVUE positions and 93 closed out — a net gain of 47 holders — while 436 added to existing stakes and 328 trimmed.
The largest buyer was Vanguard Group, adding an estimated $877M. The largest seller was Johnson & Johnson, exiting entirely with an estimated $3.91B sold.
- 995 institutional investors held Kenvue (KVUE) as of Q2 2024, up from 963 in Q1 2024.
- Funds reported $34.1B of Kenvue stock for Q2 2024, down 15% quarter-over-quarter.
- 140 funds opened new Kenvue positions in Q2 2024 and 93 closed out, a net change of +47 holders.
- The largest Kenvue buyer in Q2 2024 was Vanguard Group, an estimated $877M added.
- The largest Kenvue seller in Q2 2024 was Johnson & Johnson, an estimated $3.91B sold.
Based on aggregated 13F filings for Q2 2024.